anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study was a single-arm, prospective, exploratory clinical trial to explore the pathological complete response (pCR) rate of immune checkpoint inhibitors combined with antibody conjugate drugs as the perioperative treatment of platinum-intolerant bladder cancer patients. Fifty-five patients with clinically or pathologically confirmed muscle-invasive bladder urothelial carcinoma (MIBC) who were ineligible for cisplatin-based chemotherapy or refused cisplatin-based chemotherapy were enrolled. Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles before surgery. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles after surgery. The efficacy was evaluated and followed up after 4 cycles of neoadjuvant therapy, 3 months postoperative, and every 3-6 months thereafter. The primary endpoint of this study was pathological complete response rate (pCR). The secondary endpoints were to explore the safety, disease-free survival (DFS), overall survival (OS), objective response rate (ORR) and disease control rate (DCR) of RC48 combined with toripalimab neoadjuvant therapy followed by radical cystectomy. In the process of research, plasma and tumor tissues need to be obtained for proteomics and genomics analysis to explore the relationship between potential predictive biomarkers and efficacy.
The administration of ranitidine as a continuous infusion has not been evaluated in patients with impaired renal function. On the basis of experience with a group of subjects with severely impaired renal function treated with ranitidine hydrochloride, the recommended dosage in patients with a creatinine clearance <50 mL/min is 50 mg every 18 to 24 hours. Should the patient's condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating ranitidine. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.

Elderly patients are more likely to have decreased renal function, therefore caution should be exercised in dose selection, and it may be useful to monitor renal function (see CLINICAL PHARMACOLOGY: Pharmacokinetics: Geriatric Use and PRECAUTIONS: Geriatric Use).
The foot is a complex structure comprising numerous bones, muscles, and ligaments that work together to provide support and facilitate movement. It is supported by three arches: the medial longitudinal arch, the lateral longitudinal arch, and the transverse arch. The medial longitudinal arch plays a crucial role in absorbing weight, but issues like ligament laxity and muscle weakness can cause it to shorten, leading to conditions like plantar fasciitis. Plantar fasciitis, a common overuse injury, occurs when the plantar fascia, a fibrous tissue that supports the arch of the foot, becomes inflamed due to repetitive strain, especially during activities that increase its stretch, such as barefoot walking or stair climbing. People with flat feet are more susceptible to plantar fasciitis due to the overstretching of the plantar fascia caused by the lack of arch support.

Navicular drop, a measure of the navicular bone height, also plays a significant role in foot biomechanics and the development of plantar fasciitis. High navicular height leads to increased foot pronation and tension on the plantar fascia, while low navicular height causes overpronation and arch collapse, both of which can result in inflammation of the plantar fascia. Physiotherapists use techniques like navicular mobilization to address issues related to the navicular bone and improve blood circulation, healing, and pain relief in cases of plantar fasciitis. By understanding the biomechanics of the foot and employing targeted interventions, healthcare professionals can help manage and prevent conditions like plantar fasciitis, allowing individuals to maintain optimal foot health and functionality.
The spread of chlamydia indicates that current preventive work with condoms is insufficient. Research shows that reasons behind increased chlamydia include youths taking more sexual risks, due to altered attitudes and sexual behaviors. Since only condoms protect against both sexually transmitted infections (STIs) and unwanted pregnancy, the goal of the World Health Organization (WHO) chlamydia prevention program is to increase condom use. Research suggests that school is the most important arena for sex education, reaching all youths early in life, when many values on sex and relationships are instilled. International studies on theater in sex education indicate effects like increased knowledge on the topic, and partially changed attitudes and behaviors among youths. Furthermore, several studies show that youths feel theater is a good method for sex education and a supplement to standard education.
The invention relates to the field of genetic engineering, in particular to a target protein of Parkinson's Disease (PD), a coding gene and application thereof, and especially relates to preparation of a gene-targeted drug aiming at the key gene. The invention finds that the target genes ZIP13 and transferrin (Tsf) of the Parkinson disease are provided, and the Tsf is interfered by overexpression of ZIP13 or gene silencing to obviously relieve or delay the PD condition. According to the invention, the target protein of human PD comprises the amino acid sequences shown as SEQ ID No.5 and SEQ ID No.6, and the gene comprises the nucleotide sequences shown as SEQ ID No.7 and SEQ ID No. 8. According to the target gene, an RNAi vector carrying the target gene is constructed, and the RNAi vector can be used for improving the motor ability of a PD patient and relieving or preventing PD symptoms caused by the knocked-down PINK1 through gene silencing or gene overexpression. The invention is expected to provide a new treatment strategy and a key target for treating hereditary PD.
BACKGROUND: Cancer affects mental health in older adults with cancer (OAC), affecting almost 50% of the patients. There are only a few studies on psychiatric disorders in OAC, especially in low resource settings. We report on our real-world experience of prevalence of and factors associated with psychiatric disorders in OAC referred to a psycho-oncology service in an Indian tertiary care cancer institute.
METHODS: We retrospectively analysed medical and psycho-oncology records of patients aged 60 + on cancer-directed treatment or follow-up for < 2 years after treatment completion, referred to psycho-oncology services in a tertiary care cancer centre in Mumbai, India, from Jan 2011-Dec 2017. We recorded sociodemographic, clinical, and treatment-related variables, as well as past psychiatric disorders. The ICD-10 was used to record current psychiatric disorder type and presence. IBM SPSS version 24 (Armonk, NY, USA) was used for descriptive measures, tests of association, and logistic regression analysis. The study protocol was approved by Institutional Ethics Committee and registered with the Clinical Trials Registry-India (CTRI/2020/06/026095).
RESULTS: Of 763 patients included in the study, 475 (62.3%) were males and 436 (57.1%) were inpatients, with a median age of 65 years. 93% of the patients had a solid tumour and 207 (27.1%) had a history of psychiatric disorder. A current psychiatric diagnosis was noted in 556 patients (72.9%) on initial presentation, of which adjustment disorders, delirium and depression and anxiety disorders were most frequently seen in 25.2%, 21% and 11.1%, respectively. On univariate analysis, a past history of psychiatric disorders (χ2 = 34.6, p < 0.001), lower performance status (χ2 = 9.9, p = 0.002) and haematolymphoid malignancy (χ2 = 4.08, p = 0.04) significantly increased the risk of current psychiatric diagnosis. Logistic regression confirmed these variables as significant.
CONCLUSION: Older adults with cancer referred to psycho-oncology services have high rates of psychiatric disorders at their initial presentation, mainly adjustment disorders, delirium and depression and anxiety. A past history of psychiatric disorders, lower performance status and haematolymphoid cancers significantly increased the risk of psychiatric disorders. Multidisciplinary psycho-oncology teams including a psychiatrist should be integrated in comprehensive care of this group of patients. Further research outcomes and effect of psycho-oncological interventions is required in older adults with cancer in LMIC settings.
NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the "self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border" as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time.
INTRODUCTION: Pancreatic adenocarcinoma (PDAC) is becoming a public health issue with a 5-years survival rate around 10%. Patients with PDAC are often sarcopenic, which impacts postoperative outcome. At the same time, overweight population is increasing and adipose tissue promotes tumor related-inflammation. With several studies supporting independently these data, we aimed to assess if they held an impact on survival when combined.
METHODS: We included 232 patients from two university hospitals (CHU de Lille, Institut Paoli Calmette), from January 2011 to December 2018, who underwent Pancreaticoduodenectomy (PD) for resectable PDAC. Preoperative CT scan was used to measure sarcopenia and visceral fat according to international cut-offs. Neutrophil to lymphocyte (NLR) and platelet to lymphocyte ratios (PLR) were used to measure inflammation. For univariate and multivariate analyses, the Cox proportional-hazard model was used. P-values below 0.05 were considered significant.
RESULTS: Sarcopenic patients with visceral obesity were less likely to survive than the others in multivariate analysis (OS, HR 1.65, p= 0.043). Cutaneous obesity did not influence survival. We also observed an influence on survival when we studied sarcopenia with visceral obesity (OS, p= 0.056; PFS, p = 0.014), sarcopenia with cutaneous obesity (PFS, p= 0.005) and sarcopenia with PLR (PFS, p= 0.043). This poor prognosis was also found in sarcopenic obese patients with high PLR (OS, p= 0.05; PFS, p= 0.01).
CONCLUSION: Sarcopenic obesity was associated with poor prognosis after PD for PDAC, especially in patients with systemic inflammation. Pre operative management of these factors should be addressed in pancreatic cancer patients.
Coordinator of project has strong expertise in cardiovascular research and especially in ACS, PCI and antiplatelet therapy. The group led by pr Bonello has published several articles (appendix 3) including the VASP studies which have been presented at major cardiologic congresses (late breaking trials ACC 2007, AHA 2008, TCT 2011, EuroPCR 2010) including physicians and biologists. The group is composed of international experts in this research field (Pr Bonello, Pr Cuisset, Dr Barragan, Pr Lemesle). Additionally, coordinator center has a strong expertise in clinical research and a methodological support will be provided by the Clinical Research Platform of the AP-HM (responsible: Prof. Pascal Auquier, medical referent: Dr Karine Baumstarck).

The project brings together investigators that have been previously involved in many clinical studies in the field of ACS and PCI. In particular they have joined forces on multicenter trials leaded by the cardiology department of the Hôpital Universitaire Nord de Marseille (the VASP studies, the Early clinical trial) and they have regular meetings to share scientific data and research program design and advancement. There is a good capacity and ability of recruitment by the partner centers. The procedures to perform in this project are very simple and the disease is frequent. These are good criteria for the feasibility.
We describe a male patient presenting with cerebellar ataxia and behavioural frontotemporal dementia in whom imaging showed cerebellar atrophy. He had significantly low N-acetyl aspartate to creatine (NAA/Cr) area ratio on MR spectroscopy of the cerebellum, primarily affecting the vermis. CT body scan showed extensive abnormal tissue within the mesentery, the retroperitoneum and perinephric areas. PET-CT showed increased tracer uptake within the wall of the aorta suggestive of an aortitis and within the perinephric tissue bilaterally. Biopsy of the perinephric tissue confirmed IgG4 disease. Treatment with steroids and mycophenolate improved his clinical state, but he developed symptoms attributed to pericardiac effusion that necessitated treatment initially with drainage and subsequently with pericardial window. After a course of rituximab, he had an episode of sepsis that did not respond to appropriate treatment and died as a result. Both the imaging findings and neurological presentation with cerebellar ataxia and behavioural frontotemporal dementia are novel in the context of IgG4 disease.
The invention belongs to the technical field of disinfection protection, and particularly relates to a composition for inhibiting pathogenic microorganisms. The active components of the composition are as follows: from a compound containing a free thiol group (e.g. N-acetylcysteine) and a zinc salt (e.g. zinc gluconate or zinc acetate). The invention also provides a bacteriostatic agent which consists of potassium sorbate, N-acetylcysteine, methionine, zinc acetate dihydrate, zinc gluconate, ascorbic acid, sodium metabisulfite, polyvinylpyrrolidone and a solvent, wherein the solvent consists of purified water, glycerol and ethylene glycol phenyl ether according to a volume ratio of 84:15:1. The antibacterial agent has strong inhibition effect on pathogenic microorganisms such as candida albicans, staphylococcus aureus, escherichia coli and the like, and the antibacterial rate can reach more than 90%, so that the antibacterial agent is an ideal disinfection product.
Despite the advances in the immunosuppressive therapies and improvements in short term allograft survival, Antibody-mediated rejection (AMR) still represents the leading cause of late allograft failure in kidney transplant recipients. We present an insidious case of late active AMR that evolved into a severe chronic active antibody-mediated rejection, that we treated with a multidrug approach. Then, we review the current literature on the pathogenesis, diagnosis and treatment of AMR. Antibody-mediated rejection (AMR) typically occurs when anti-HLA donor-specific antibodies (DSA) bind to vascular endothelial cells of the kidney graft. DSAs may preexist to transplantation (preformed DSA) or develop after transplantation (de novo DSA). Pathogenetic mechanisms of AMR involve complement-dependent, and -independent inflammatory pathways that are variably activated depending on antigen and antibody characteristics, or on whether rejection develops early (0-6 months) or late (beyond 6 months) post-transplantation. The Banff classification system categorizes AMR rejection into active antibody-mediated rejection, chronic active antibody-mediated rejection, and chronic (inactive) antibody-mediated rejection. Currently, there are no approved therapies, treatment guidelines being based on low-quality evidence. Therefore, standard of care therapy is consensus-based. In early rejection, it is usually based on plasma exchange, intravenous immune globulin, anti-CD20 antibodies, while complement-inhibitor eculizumab is used in severe and/or refractory cases, treatments with. Recent evidence suggests that late AMR may be effectively treated with anti-CD38 therapy, which targets long lived plasma cells and NK cells.
For the first dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed. For the second dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
PROBLEM TO BE SOLVED: To obtain an emulsified composition excellent in both biological safety and emulsion stability with time, good in feeling when used, and excellent in fluidity esp. when rendered liquid, by using, as an emulsifier, a combination of lecithin compound(s) with other specific emulsifying component(s). SOLUTION: This emulsified composition is obtained by using, as an emulsifier, a combination of a lecithin and/or a lecithin derivative with cholesterol and/or a cholesterol ester in the weight ratio of pref. 1:(0.01-1.6), esp. 1:(0.08-0.5). The lecithin is e.g. a phytolecithin derived from soybean, rapeseed, sunflower or safflower, a zoolecithin derived from yolk, etc. The lecithin derivative is e.g. hydrogenated lecithin, lecithin hydroxide. The cholesterol ester is e.g. a lanoline fatty acid cholesteryl ester. This emulsified composition is of O/W type, being normally in the form of liquid, and applicable as a cosmetic or medicinal base for external use.
The crosstalk between cuproptosis and the tumor immune microenvironment (TIME) is vital during clear cell renal cell carcinoma (ccRCC) malignant progression. However, the underlying molecular mechanisms regulate this cross-talk remain elusive. Through tailored machine learning, we analyze clinical ccRCC data from The Cancer Genome Atlas (TCGA) to explore the critical factors that regulate the interaction among cuproptosis, TIME, and tumor progression. We found that rhomboid-like 2 (RHBDL2), critical gene affecting this process, might inhibit cuproptosis-related genes (CRGs) and promotes ccRCC progression through the Wnt/β-catenin pathway. Next, knocking down RHBDL2 expression increased the cuproptosis-related genes ferredoxin 1 (FDX1) and lipoic acid synthase (LIAS) levels but reduced forkhead box P3 (FOXP3) levels and tumor growth in vivo and in vitro models. By employing HLY78, Wnt/β-catenin pathway activator, we rescued the expression of CRGs and the malignant proliferation and metastasis capacity in ccRCC cells with RHBDL2 knockdown. Mechanistically, RHBDL2 inhibits cuproptosis and promotes malignant progression of ccRCC through the Wnt/β-catenin pathway. Abnormal RHBDL2 expression may cause the suppressive TIME formation by regulating Treg-cell infiltration, thus triggering immune escape. In summary, our results indicated that RHBDL2 is an oncogene that induces tumorigenesis and targeting RHBDL2 may be novel therapeutic direction for metastatic ccRCC.
Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
The title proteins, which contain as the active gp. the peptide sequence-Asp-Gly-Ser-Glu-Met- are prepd. by treating a tubercle bacillus with an organic solvent, digesting the resulting material with a nuclease, dialysing the resulting hydrosoluble proteins in a buffer at pH 5.5-7.8, and fractionating the hydrolysate by chromatography and/or gel filtration. Peptides contg. the same active sequence may be obtd. by hydrolysing the proteins, and fractionating the hydrolysate by chromatography and/or gel filtration. The proteins and peptides are used in the diagnosis of tuberculosis. Suitable bacilli are strains of Mycobacterium tuberculosis, e.g., Calmette and Guerin's bacillus, or M.tuberculosis strain Aoyama B.
This will be a delayed treatment arm. Participants randomized to the waitlist control group will be re-randomized after completing the no treatment period of 12 weeks to CBGT or MBSR with equal probability.
The invention relates to a technology for preparing a novel sweet wormwood and turtle shell decoction integrated preparation. The preparation comprises the following effective components in parts by weight: 6 parts of sweet wormwood, 15 parts of turtle shell, 12 parts of rehmannia root, 6 parts of anemarrhena, and 9 parts of bark of tree peony. The preparation process comprises the following steps of supersonic airflow pulverizing, alcohol-water extraction, supersonic pulverizing extraction, decoction and concentration, nano-grinding, high-pressure homogenization, nano-particle preparation and the like. The technology pays attention to the application of the advantages of multi-collaboration multi-target and the like represented by a nano-carrier combination technology. After the technology is applied to production in scale, the production cost can be greatly reduced, the product quality can be greatly improved, and the targeting and sustained release performance of the medicament can be stronger. The preparation can be administrated internally and externally simultaneously, can be taken in four time segments respectively according to midnight-noon ebb-flow and human body qi-blood flowing rule, also can be prepared to form a film-forming agent and transdermal agent to be applied to different positions of a human body respectively according to the midnight-noon ebb-flow and human body qi-blood flowing rule, and can be directly absorbed through skin.
The present invention provides a method of inducing the formation of insulin-producing cells which comprises transferring a pancreatic β-cell associated transcriptional factor gene into the pancreas to induce the formation of insulin-producing cells. The pancreatic β-cell associated transcriptional factor gene is transferred into the pancreatic tissue stem cells by the ICBD injection without ligating the common bile ducts and thus the formation of insulin-producing cells is induced. In the present invention, pdx-1, neurogenin3, etc. are used as such pancreatic β-cell associated transcriptional factor gene and an adenoviral vector with the use of the Cre-loxP recombination system, etc. is used as a vector for transferring the pancreatic β-cell associated transcriptional factor gene into the pancreas. The method of the invention enables regeneration therapy for diabetes mellitus by inducing the formation of insulin-producing cells.
Within the framework of its Market Insights Program, AMCP convened a panel of experts representing diverse stakeholders to identify alterations to plan design and/or coverage options geared toward improving the diagnosis and treatment of mental health conditions among persons living with rare diseases (PLWRD). PLWRD face unique mental health challenges because of the misunderstood nature of their conditions, potential misdiagnosis, and limited treatment options. Economic burdens arise from increased medical needs, reliance on caregivers, and work disruptions. The interplay of these factors, along with health insurance coverage, creates a distinctive mental health landscape for PLWRD and a need to prioritize mental health support for this patient population. This article aims to (1) summarize expert perspectives on health care system challenges and areas of agreement concerning the management of mental health conditions and (2) advance payers' understanding of their role in supporting mental health care for patients with rare diseases. Addressing mental health needs of PLWRD presents multifaceted challenges. Managed care organizations play a pivotal role in supporting mental health care for PLWRD through their quality improvement initiatives and policies for coverage and reimbursement, which can impact both the rare disease treatment and mental health services PLWRD receive.